Lb Pharmaceuticals (LBRX) Debt to Equity (2024 - 2026)

Lb Pharmaceuticals has reported Debt to Equity for 3 years, with the latest figure at $0.0 in Q1 2026.

• For the quarter ending Q1 2026, Debt to Equity changed N/A year-over-year to $0.0; the trailing twelve-month figure through Mar 2026 stood at $0.0 (changed N/A YoY), and the FY2025 full-year result was $0.0, up 116.83% from the prior year.
• Debt to Equity for Q1 2026 stood at $0.0, down from $0.0 in the prior quarter.
• The five-year high for Debt to Equity was $0.0 in Q4 2025, with the low at -$0.03 in Q4 2024.
• Average Debt to Equity over 3 years is -$0.0, with a median of $0.0 recorded in 2026.
• Peak annual rise in Debt to Equity reached 116.83% in 2025, while the deepest fall reached 116.83% in 2025.
• Tracing LBRX's Debt to Equity over 3 years: stood at -$0.03 in 2024, then jumped by 116.83% to $0.0 in 2025, then sank by 32.28% to $0.0 in 2026.
• The last three Debt to Equity figures came in at $0.0 (Q1 2026), $0.0 (Q4 2025), and $0.0 (Q3 2025), per Business Quant data.

Peer Comparison